Literature DB >> 1396707

Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat.

T Koga1, K Fukuda, Y Shimada, M Fukami, H Koike, Y Tsujita.   

Abstract

Tissue selectivity of pravastatin sodium (pravastatin), lovastatin and simvastatin, 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors was examined by measuring inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rats after a single oral administration (25 mg/kg) of these drugs. Regarding tissue drug concentrations, all three drugs were liver selective: concentrations of drugs in the liver were about ten-times higher than those in the spleen and testis. On the other hand, pravastatin was far more liver selective in inhibiting sterol synthesis than two other inhibitors: pravastatin inhibited de novo sterol synthesis in the liver but minimally in the spleen and testis, whereas lovastatin and simvastatin inhibited in all three tissues. Microautoradiographic and in vitro cellular-uptake studies demonstrated that pravastatin remained in the extracellular space in the spleen, whereas the other drugs entered the cell. We conclude that pravastatin exhibits a liver-selective inhibition of sterol synthesis because the agent permeates the cell membrane in the liver, but not in non-hepatic tissues.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1396707     DOI: 10.1111/j.1432-1033.1992.tb17291.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  13 in total

1.  Pharmacokinetic and pharmacodynamic evaluation for tissue-selective inhibition of cholesterol synthesis by pravastatin.

Authors:  T Hatanaka; S Honda; S Sasaki; K Katayama; T Koizumi
Journal:  J Pharmacokinet Biopharm       Date:  1998-06

2.  Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres.

Authors:  K Sakamoto; H Mikami; J Kimura
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

Review 3.  Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.

Authors:  T Hatanaka
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

Review 4.  Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.

Authors:  H Lennernäs; G Fager
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

5.  Tissue-selective inhibition of sterol synthesis in mice by pravastatin sodium after a single or repeated oral administrations.

Authors:  T Koga; T Kikuchi; A Miyazaki; H Koike
Journal:  Lipids       Date:  1995-08       Impact factor: 1.880

Review 6.  Pravastatin: a review of its use in elderly patients.

Authors:  Lynne M Bang; Karen L Goa
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  Inhibition of cholesterol synthesis ex vivo and in vivo by fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.

Authors:  A Yamamoto; S Itoh; K Hoshi; K Ichihara
Journal:  Experientia       Date:  1995-03-15

8.  Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts.

Authors:  K Satoh; A Yamato; T Nakai; K Hoshi; K Ichihara
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

9.  Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2?

Authors:  Ryuji Kato; Mami Nishide; Chihiro Kozu; Asuka Iwamoto; Kazuya Urashima; Kaoru Suzuki; Yoshio Ijiri; Tetsuya Hayashi; Kazuhiko Tanaka
Journal:  Eur J Clin Pharmacol       Date:  2009-10-13       Impact factor: 2.953

10.  Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.

Authors:  Christopher Rowan; Allen D Brinker; Parivash Nourjah; Jennie Chang; Andrew Mosholder; Jeffrey S Barrett; Mark Avigan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-04       Impact factor: 2.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.